lupus Flashcards

1
Q

SLE: Loss of tolerance to ______ leads to immune system mediated damage to self

A

self

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

SLE is rarer than RA?

A

yep At most one hundredth of RA

Female predominance (7-15:1)
In children and older lupus populations this ratio is not as high.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Increased frequency in close relatives
30-50% concordance in monozygotic twins
Ethnic and racial susceptibilities may support genetic influence
HLA-DR2 and –DR3: weak associations
STAT4 (a transcription factor) gene variant allele on chromosome 2 confers increased risk of rheumatoid arthritis and SLE

A

genetic factors of SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SLE central defect

A

apoptosis

Increased frequency in close relatives
30-50% concordance in monozygotic twins
Ethnic and racial susceptibilities may support genetic influence
HLA-DR2 and –DR3: weak associations
STAT4 (a transcription factor) gene variant allele on chromosome 2 confers increased risk of rheumatoid arthritis and SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

_____________ activation and its activation of the innate immune response may play a central role in perpetuating the autoreactive immune response

A

Toll-like receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

A strong ___________ is a hallmark of the cytokine profile in SLE. Mimics what might be seen in a chronic viral infection

A

interferon-1 induced gene transcript signature (with IFN-α the dominant mediator)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

SLE _________ serum complement levels are a marker for disease activity (particularly C3 and C4)

A

decreased

Activates complement cascade so abundantly that one sees complement depleted/consumed faster than it can be made

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SLE marker for disease activity

A

Anti-dsDNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

most specific ab but no correlation with disease activity

A

anti-Sm(ith)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Anti SSA (Ro), -SSB (La)

A

seen in both SLE and sjorgen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tregs cells are diminished in number and activity

A

yea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anti-RNP –

A

seen in SLE and “mixed connective tissue disease”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Antiphospholipid antibodies (APLA)

A

when pathogenic - thrombosis, fetal loss

Anticardiolipin, lupus anticoagulant, false + VDRL all represent APLA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Immune complexes in SLE

A

deposition in vessels and tissues initiates inflammation leading to damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
Constitutional symptoms – nonspecific but can be profound (which do we see?)
Fatigue
Weight loss
Fever, sweats, chills
Lymphadenopathy
A

all of these can be seen in SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Inflamation of muscles with release of muscle enzymes. Only rarely progresses to actual weakness thus usually a laboratory finding (elevation of creatine phosphokinase)

A

Myositis –

17
Q

cutaneous manifestations

A
  1. malar rash- in 50% brought on by photosensitive, transient or chronic and similar appearing rashes seen in pregnancy
  2. photosensitivity- 50%
  3. discoid annular scaly plaques; scarring , head and neck arms
  4. subacute cutaneous lupus- small erythematous papules that coalesce into patterns; nonscarring
  5. bullous lupus rashes
  6. alopecia
  7. vascular- raynaud’s, telangiectasia
18
Q

. Deposits of multiple immune elements such as complement components and immunoglobulins (eg: IgM, IgG, etc)) may be found at the dermal-epidermal juncture

A

Positive lupus band test in SLE skin

19
Q

Probably the most morbid manifestation of SLE. This used to be a major cause of mortality in the pre-steroid era.

A

lupus nephritis

Nearly all patients have EM and immunofluorescent renal abnormalities; 50% have clinically apparent disease.
Usually but not always occurs in the first years of the disease.

20
Q

what happens in lupus nephritis?

A

immune complexes and complement deposit in glomeruli in capillary wall, subepithelium, subendothelium, and mesangium invoking inflammation and cellular proliferative and fibrotic (scarring) response

21
Q

Urinary findings in lupus nephritis:

  • what type of cells do we see?
    • is there protein in the urine?
  • Casts?
A

Hematuria (RBC) > pyuria (WBC)
Proteinuria
Casts – RBC casts most ominous

22
Q

class II GN

A

mesangial proliferative GN

23
Q

Class III GN

A

focal proliferative GN

24
Q

Class IV GN

A

diffuse proliferative GN

25
For guiding treatment in SLE GN: Class I and II (mesangial) Class III and IV (proliferative GN) Class V (membranous) - In longstanding cases biopsy helps show the degree of permanent damage that will not be treatment responsive
Class I and II (mesangial) – may treat gingerly or not at all and watch closely for any transition to more aggressive histology Class III and IV (proliferative GN) warrant steroids and other immunosuppressive therapy Class V (membranous) - different treatment algorithm
26
worst Class GN prognosis
Class IV
27
an alkylating agent that works by slowing or stopping cell growth; greatest impact on most activated cells Also used as chemotherapeutic agent in some cancer treatments
cyclophosphamide (cytoxan)
28
an inhibitor of inosine-5'-monophosphate dehydrogenase. It depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation Major use in preventing transplant rejection
mycopenolate (cellcept)
29
_____________ significantly reduced the risk of renal failure at 9+ years compared to oral corticosteroids alone
Cyclophosphamide
30
____________ has become the treatment of choice for proliferative lupus nephritis due to its favorable toxicity profile
Mycophenolate
31
pulmonary manifestations in SLE (3)
1. pleurisy 2. interstitial inflammation- pneumonitis 3. vascular disease- PHTN
32
Cardiac manifestations in SLE (4)
1. CAD 2. pericardial involvment 3. myocardial involvement 4. endocardial involvement- libman-sacks verrucous
33
libman-sacks
verrucous endocarditis- immune complex deposition at valve edge
34
neuropsychiatric lupus (2)
1. diffuse cerebral dysfunction | 2. focal cerebral dysfunction- hypercoag. leading to stroke
35
what is the target site in the glomerulus that leads to the highest risk of kidney failure?
glomerular endothelial cells
36
management of SLE (3)
1. antimalarials such as hydroxychloroquine 2. corticosteroids for flares 3. biologic therapies that target b-cell suppression
37
An ANA of 1:80 or greater is necessary in order for a patient to fulfill criteria
yep